GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Next Science Ltd (ASX:NXS) » Definitions » Liabilities-to-Assets

Next Science (ASX:NXS) Liabilities-to-Assets : 0.28 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Next Science Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Next Science's Total Liabilities for the quarter that ended in Dec. 2023 was A$7.59 Mil. Next Science's Total Assets for the quarter that ended in Dec. 2023 was A$26.74 Mil. Therefore, Next Science's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 was 0.28.


Next Science Liabilities-to-Assets Historical Data

The historical data trend for Next Science's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Next Science Liabilities-to-Assets Chart

Next Science Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Liabilities-to-Assets
Get a 7-Day Free Trial 0.15 0.20 0.22 0.36 0.28

Next Science Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.25 0.36 1.00 0.28

Competitive Comparison of Next Science's Liabilities-to-Assets

For the Drug Manufacturers - Specialty & Generic subindustry, Next Science's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Next Science's Liabilities-to-Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Next Science's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Next Science's Liabilities-to-Assets falls into.



Next Science Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Next Science's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Liabilities-to-Assets (A: Dec. 2023 )=Total Liabilities/Total Assets
=7.588/26.743
=0.28

Next Science's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 is calculated as

Liabilities-to-Assets (Q: Dec. 2023 )=Total Liabilities/Total Assets
=7.588/26.743
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Next Science  (ASX:NXS) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Next Science Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Next Science's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Next Science (ASX:NXS) Business Description

Traded in Other Exchanges
Address
821 Pacific Highway, Suite 1902, Level 19, Tower A, The Zenith Building, Chatswood, NSW, AUS, 2067
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Its products include Bactisure, SURGX, XEPERIENCE and BLASTX. The company derives revenue from the U.S. and Australia, of which prime revenue is derived from the U.S.

Next Science (ASX:NXS) Headlines

No Headlines